Contact details of Key Managerial Personnel who are authorized for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s) as required under SEBI (LODR) Regulations,2015:
Yiu Kwan Stanley Lau is the Chairman and Independent Director of our Company. He holds a bachelor’s degree
in pharmacy from The School of Pharmacy, University of London. He is a director on the board of directors
Solasia Pharma K. K. and TaiLai Bioscience Ltd. He was previously the chief executive officer of Amsino
Medical Group, the chief operating officer of Eddingpharm Investment Co. Ltd, and the president of China
Biologic Products, Inc. He has also worked with Merck Sharp & Dohme (Asia) Ltd and Baxter (China) Investment
Co., Ltd.
Mr. Srinivas Sadu
Executive Chairman
Mr. Sadu has joined Gland Pharma in 2000 and rose up the ranks to become Chief Operating Officer in 2011 and Managing Director & CEO in 2019. He holds a Master's degree in Industrial Pharmacy from Long Island University, New York; MBA from University of Maryland, Baltimore; and Postgraduate Certification in Finance and Management from London School of Business and Finance.
Prior to joining Gland Pharma, Mr. Sadu worked as Product Manager & Business Lead at Natco Pharma for two years & as Product Manager for Consumer Health Care at SmithKline Beecham.
He has over 24 years of experience in Business Development, Manufacturing Operations, Supply Chain Management and Strategic Planning.
Under his leadership, the Company has consistently witnessed growth, both in terms of revenue and profits, while expanding across all geographies, and got listed on NSE and BSE in the year 2020. Mr. Srinivas Sadu has been appointed as Executive Chairman of the Company with effect from 16th January 2025.
Mr. Xingli Wang
Non-Executive and Non-Independent Director
Mr. Xingli Wang is the Non-Executive and Non-Independent Director of the Company. He is currently the President of Fosun Pharma, and holds positions including the Chief Executive Officer of the Global R&D Center and Chief Executive Officer of innovative medicine division, Fosun Pharma and Non-Executive Director of Shanghai Henlius (stock code: 02696), a subsidiary listed on the Hong Kong Stock Exchange.
Mr. Wang joined the Fosun Group in January, 2023 and served as the Executive President of Fosun Pharma from January, 2023 to June, 2025. Prior to joining the Fosun Group, Mr. Wang served as a Senior lecturer in Cardiovascular Medicine at The University of New South Wales (“UNSW”), Australia, and as a cardiologist and professor with tenure at Baylor College of Medicine, USA, Medical Director of Schering-Plough Corporation, a company formerly listed on the New York Stock Exchange (stock code: SGP) (merged into Merck & Co., Inc. in 2009). He also worked in Novartis AG (stock code: NVS), a company listed on the New York Stock Exchange, where he successively served as Project Supervisor, Global Project Clinical Head, Head of Novartis Global Drug R&D (China) and General Manager of Biomedical Research Institute (China).
Mr. Wang obtained a Bachelor’s degree in Medicine from Shandong Medical College (merged into Shandong University in 2000) and a Doctorate degree in Cardiovascular Science from the UNSW. Mr. Wang also holds a license to practice Medicine in Australia.
Mr. Yifang Wu
Non-Executive Director
Yifang Wu is a Non-Executive Nominee Director of our Company. He holds a masters of administration in
communication from Saint Joseph’s University (Philadelphia). He has over 30 years of experience in the
pharmaceutical industry. He commenced his career as an employee of Xuzhou Biochemical Pharmaceutical Factory
(now known as Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd) in June 1987. He was the chairman and
chief executive officer of Wanbang Biopharma from April 2011 to July 2020. He has been associated with
Shanghai Fosun Pharmaceutical (Group) Co., Ltd since 2004, and is presently the Chairman and CEO of Shanghai
Fosun Pharmaceutical (Group) Co. Ltd.
Mr. Frank Yao
Non-Executive Director
Yao Fang is a Non-Executive Nominee Director of our Company. He holds a bachelor’s degree in Economics from
Fudan University and a Master’s degree in Business Administration from The Chinese University of Hong Kong.
He is the Executive President of Fosun International Limited. He joined the Fosun Group in April 2010 and he
is also a Non-Executive Director of Shanghai Fosun Pharmaceutical (Group) Co. Ltd.
Ms. Xiaohui Guan
Non-Executive Director
Xiaohui Guan is a Non-Executive Nominee Director of our Company. She holds a master’s degree in
professional accountancy from the Chinese University of Hong Kong. She is also a member of the ACCA
(Association of Chartered Certified Accountants) and a non-practising member of the Chinese Institute of
Certified Public Accountants. She joined the Fosun group in May 2000. She is the executive president and
chief financial officer of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and non-executive director of
Sinopharm Group Co., Ltd.
Mr. Udo Johannes Vetter
Independent Director
Udo Johannes Vetter is an Independent Director of our Company. He holds a bachelor’s degree in science
(pharmacy) from the University of Washington. He has been associated with the Vetter/ Vetter Pharma group of
companies since 1987, and is currently the chairman on the board of directors of Vetter Pharma
(Corporation).
Mr. Essaji Goolam Vahanvati
Independent Director
Essaji Goolam Vahanvati is an Independent Director of our Company. He holds a bachelor’s degree in law from
Government Law College, Mumbai. He is an independent legal practitioner, practising in the Supreme Court of
India and Delhi High Court.
Mr. William Robert Keller
Independent Director
Mr. William Robert Keller, is an Independent Director of our Company. He holds a Bachelor of Science degree from the School of Economics and Business Administration in Zurich, Switzerland, in July, 1972. Mr. Keller currently also serves as an Independent Director on the Boards of Wuxi Biologics, listed on Hongkong Stock Exchange; and Hua Medicine, listed on Hongkong Stock Exchange.
Ms. Naina Lal Kidwai
Independent Director
Naina Lal Kidwai is an Independent Director of our Company. She holds Bachelors degree in Economics from Delhi University and Masters of business administration from Harvard Business School. She is recipient of many prestigious awards including the Padma Shri by the Government of India for her contribution to Trade and Industry. She is presently the Chairman of Advent Private Equity India Advisory board; a Non- Executive Director on the Boards of LafargeHolcim, Max Financial Services, and Cipla; a Trustee of Asia House in the UK; India Advisory Council, Member of the U.S.-India Business Council (USIBC); and was the Past President of the Federation of Indian Chambers of Commerce and Industry (FICCI).
Dr. Jia Ai Zhang
Non-Executive and Non-Independent Director
Dr. Jia Ai Zhang is a Non-Executive and Non-Independent Director of our Company. He holds a Bachelor Degree in Pharmacy from Fudan University and PhD in Pharmaceutics from Oregon State University He is currently working as Sr. Vice President with Shanghai Fosun Pharma Development Co, Ltd. and Executive President, Global R&D Center of Fosun Pharma. He is also a Director in Guilin Pharma, Yao pharma and Novelstar, of Fosun Pharma group. He was earlier associated with Zhejiang Huahai Pharmaceuticals, Frontage Labs, Yusongyuan Pharmaceuticals, Novartis Pharmaceutical Corp, NeoPharm Inc and Baxter Healthcare Corporation.
Ms. Wei Huang
Non-Executive and Non-Independent Director
Ms. Wei Huang is a Non-Executive and Non-Independent Director of our Company. She holds Master’s degree from University of Maryland in Chemical and Biochemical Engineering and Bachelor’s degree from East China University of Science and Technology in Biochemical Engineering. She is currently the President of Shanghai Henlius Biotech Inc., and also the Chairman of Aton (Shanghai) Biotech Co., Ltd. She was earlier associated with NEWA Technology Inc. and REG Life Sciences Corporation.
